Drugs that may cause toxic myopathy, presenting as muscle dysfunction w/ weakness and elevated muscle enzymes and possibly confused w/ idiopathic inflammatory myopathies (IIM) - full read review of mimickers of myositis. https://t.co/3wdLvkxcAX https://t.co/OqLjv45HXH

Subcutaneous Anifrolumab in SLE Manzi et al. have published the results of the TULIP-SC trial that showed that weekly subcutaneous (SC) anifrolumab, when given to severe SLE patients, had comparable efficacy and safety to the approved intravenous (IV) anifrolumab. https://t.co/ruZM3Qftxb

RheumNow Live is 3 weeks away, and we can't wait to see you there! Why Attend In Person? ✔ Engage directly with faculty during live Q&A ✔ Network with peers who influence and lead in rheumatology ✔ Experience the energy, pace, and collaboration that can’t be replicated https://t.co/Do8srChyXW

The 2025 Rheumatology Year in Review The year 2025 presented numerous advances in rheumatology and related inflammatory and autoimmune disorders, ranging from several new groundbreaking FDA approvals/indications, drug developments, game-changing guidelines, and practices that https://t.co/gjNesm0AWO

ANAs and Autoantibodies https://t.co/PTdXPMCqjP https://t.co/Pbtgaod3uW

FDA & Administration are deregulating artificial intelligence & promote widespread use, includes use of wearables & other AI-enabled devices. Commissioner Marty Makary updated two guidance docs defining use general wellness devices, clinical decision support software https://t.co/KnkYqCiroa

QD Clinic: Sjogren's Beyond the Dryness Caitlin Hill, FNP, and David Maniscalco, MD, Santa Rosa, CA present this QD Clinic: Sjogren's - Beyond the Dryness. https://t.co/2U4Q2aRFec https://t.co/AGq36PT9iZ

Advanced Practitioner Biologic Prescriptions for Psoriasis Advanced practice clinicians (APCs; nurse practitioners and physician assistants) deliver a large share of US dermatologic care, accounting for 37% of clinicians and 27% of dermatology visits by 2020. A current JAMA https://t.co/3NtntmpSPV

Spread of Psoriatic Disease from Skin to Joints Approximately 20-30 % of all people who suffer from psoriasis also develop painful inflammation in their joints over time. If left untreated, PsA can lead to permanent damage to bones and joints. Why the disease progresses was https://t.co/UbGHFASKvc

Retrospective study of recombinant zoster vaccine Rheumatic (RMD) pts on DMARDs (32% JAKi) (114) vs 65 normals. HZoster reactivation: no controls vs 1in RMD. 1 Dz flare requiried steroids. Minor AE (ISR, HA, myalgia) seen in 17.5% & 21.5% w/ 1st & 2nd dose. RZV is safe in RMD https://t.co/Mu3OyA4EOD

Metanalysis of 21 clinical trials, 2,100 adults, shows cannabis-based medicines (vs placebo) over 2-26 weeks are not effective in treating chronic neuropathy nerve pain, regardless if given as THC of CBD. https://t.co/ZOJrcMGZkr https://t.co/nqCWoFmaWp